0001181431-13-033354.txt : 20130606
0001181431-13-033354.hdr.sgml : 20130606
20130606215242
ACCESSION NUMBER: 0001181431-13-033354
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130604
FILED AS OF DATE: 20130606
DATE AS OF CHANGE: 20130606
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: OR
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-444-8424
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Price Ben Gil
CENTRAL INDEX KEY: 0001417915
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 13898765
MAIL ADDRESS:
STREET 1: 801 INSPIRATION LANE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
rrd382721.xml
FORM 4
X0306
4
2013-06-04
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001417915
Price Ben Gil
215 FIRST STREET, SUITE 7
CAMBRIDGE
MA
02412
1
0
0
0
Common Stock
2013-06-04
4
A
0
1000
0
A
34830
D
Non-Qualified Stock Option (right to buy)
34.9200
2013-06-04
4
A
0
20000
0
A
2014-06-04
2023-06-04
Common Stock
20000
20000
D
On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders.
Grant of restricted stock, which shall vest in full on the anniversary date of the grant.
This option will vest at a rate of 25% annually over four years beginning on the first anniversary of the date of grant.
By: David Tyronne Howton For: Ben Gil Price
2013-06-06